# EDGAR Filing Document

**Accession Number:** 0001376339
**File Stem:** 0001376339-26-000021
**Filing Date:** 2026-4
**Character Count:** 10085
**Document Hash:** da5a2692a54baf0a96367b4e3b247ecf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001376339-26-000021.hdr.sgml**: 20260416

**ACCESSION NUMBER**: 0001376339-26-000021

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260414

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260416

**DATE AS OF CHANGE**: 20260416

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MIMEDX GROUP, INC.
- **CENTRAL INDEX KEY:** 0001376339
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 262792552
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35887
- **FILM NUMBER:** 26865726

**BUSINESS ADDRESS:**
- **STREET 1:** 1775 W OAK COMMONS COURT, NE
- **CITY:** MARIETTA
- **STATE:** GA
- **ZIP:** 30062
- **BUSINESS PHONE:** (770) 651-9100

**MAIL ADDRESS:**
- **STREET 1:** 1775 W OAK COMMONS COURT, NE
- **CITY:** MARIETTA
- **STATE:** GA
- **ZIP:** 30062

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Alynx, Co.
- **DATE OF NAME CHANGE:** 20060922

?xml version='1.0' encoding='ASCII'? mdxg-20260414

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

____________________

**FORM 8-K** ____________________

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): April 14, 2026** 

**MIMEDX GROUP, INC.**

**(Exact name of registrant as specified in charter)**

---

| | | |
|:---|:---|:---|
| **Florida** | **001-35887** | **26-2792552** |
| **(State or other jurisdiction** | **(Commission** | **(IRS Employer** |
| **of incorporation)** | **File Number)** | **Identification No.)** |

---

**1775 West Oak Commons Ct., NE, Marietta GA 30062** 

**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (770) 651-9100**

____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

**☐** Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange<br>on which registered** |
| **Common Stock, $0.001 par value per share** | **MDXG** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers** |

---

On April 14, 2026, MiMedx Group, Inc. (the "Company") instituted a cost reduction initiative intended to prioritize growth opportunities, streamline operations and significantly reduce operating expenses. As part of these changes Ricci Whitlow's position of Chief Operating Officer was eliminated and she departed from the Company immediately. Ms. Whitlow's departure was not a result of a disagreement with the Company.

Also in connection with the Company's cost reduction initiative, CEO Joe Capper's base salary was reduced by 20% and the base salaries of each of the other named executive officers, CFO Doug Rice, GC/CAO William "Butch" Hulse, and CCO Kimberly Maersk-Moller, were reduced by 10%. These reductions are applicable through December 31, 2026.

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure** |

---

On April 16, 2026, the Company issued a press release announcing its cost reduction initiative. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference.

The information in this Current Report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits** |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| 99.1 | <u>[Press Release dated April 16, 2026](ex-991restructuringpress.htm)</u> |
| 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. |

---

------

**SIGNATURES**

Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | | **MIMEDX GROUP, INC.** |
| April 16, 2026 | By: | /s/ Doug Rice |
|  |  | Doug Rice<br>Chief Financial Officer |

---

## Exhibit 99.1

![](ex-991restructuringpress001.jpg)

EXHIBIT 99.1 MIMEDX Announces Restructuring and Cost Reduction Initiative Company Expects to Realize Annualized Savings of Approximately $40 Million MARIETTA, Ga., April 16, 2026 -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced a series of cost reduction initiatives intended to prioritize growth opportunities, streamline operations and significantly reduce operating expenses. As part of these changes, the position of Chief Operating Officer, held by Ricci Whitlow, has been eliminated. "On behalf of the Board and management team, I want to thank Ricci for her innumerable contributions to MIMEDX and her exceptional leadership in helping to build and scale our operations," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Ricci joined the Company at a pivotal time in the organization's history and successfully navigated us through several regulatory audits and product launches, all while helping us scale operations in support of our long-term growth aspirations. We are deeply grateful for Ricci's commitment to the organization, and we wish her the very best in all future endeavors." Mr. Capper continued, "This leadership change comes as part of a broader restructuring and cost savings initiative at MIMEDX. Over the last few months, we have conducted a detailed review of our business and supporting corporate structure. While our Surgical business continues to flourish and warrants additional investments, our Wound Care business, along with the broader market, is recovering from the January 1st Medicare reimbursement reduction at a very slow rate." "As we entered the new year, we kept the organization resourced in the event of a rapid recovery in the Wound market. Based on first quarter market behavior, it is clear the transition is happening at a more sluggish pace, and we must now make the requisite adjustments to our cost structure to ensure the future profitability of the business. As such, we have taken steps to reduce our annual operating expenses across the enterprise by approximately $40 million. We expect a one-time restructuring charge of approximately $4 million during the second quarter of 2026 associated with these changes," concluded Mr. Capper. The Company plans to provide additional commentary around the first quarter of 2026 operating and financial results and the impact of this reorganization during its quarterly conference call in late April. Forward Looking Statements This press release includes forward-looking statements, including statements regarding our expectations regarding the impact of our cost reduction initiatives and reimbursement changes. Additional forward- looking statements may be identified by words such as "believe," "expect," "may," "plan," "goal," "outlook," "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set

------

![](ex-991restructuringpress002.jpg)

EXHIBIT 99.1 forth in the forward-looking statements. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement. About MIMEDX MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company's vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com. Contact: Matt Notarianni Investor Relations 470-304-7291 mnotarianni@mimedx.com

------